Litigation Details for Novartis Pharma AG v. Incyte Corporation (S.D.N.Y. 2020)

Novartis Pharma AG v. Incyte Corporation (S.D.N.Y. 2020)

Docket	1:20-cv-00400	Date Filed	2020-01-15
Court	District Court, S.D. New York	Date Terminated
Cause	28:1332bc Diversity-Breach of Contract	Assigned To	Gregory Howard Woods III
Jury Demand	Plaintiff	Referred To	Gabriel W. Gorenstein
Parties	INCYTE CORPORATION
Patents	10,016,429; 10,596,178; 7,598,257; 7,767,675; 8,415,362; 8,722,693; 8,822,481; 8,829,013; 9,079,912; 9,814,722
Attorneys	Keith Hammeran
Firms	Kirkland & Ellis, LLP
Link to Docket	External link to docket

Details for Novartis Pharma AG v. Incyte Corporation (S.D.N.Y. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-01-15				External link to document
2020-01-15	35	Memorandum of Law in Support of Motion	8,822,481, 8,829,013, 9,079,912, 9,814,722, and 10,016,429. Compl. ¶ 26. The U.S. P.T.O.’s website’s records…and domestic patents under “Incyte Patent Rights,” there is no such list of Novartis patents appended. …Notably, the terms “Patent Rights,” “Incyte Patent Rights,” and “Novartis Patent Rights” were separately…that each of those patents is a U.S. patent owned by Incyte.6 Because Incyte patents are irrelevant under…definition; it defines “Patent Rights” as encompassing “all patents and patent applications.” Sections	External link to document
2020-01-15	63	Answer to Complaint	Incyte further admits Incyte’s United States Patent No. 7,598,257 was submitted to the FDA’s Orange Book …Incyte admits certain United States patents cover Jakafi, those patents were all invented and developed by…applicable Novartis United States patents and so there are no Licensed Patent Rights Covering ruxolitinib …discoveries and obtain relevant patents—that is, develop Licensed Patent Rights Covering …infringe a patent absent a license—and Incyte’s sales obviously can not infringe Incyte’s own patents. In	External link to document

Last updated: June 22, 2026

ecutive summary
Novartis Pharma AG v. Incyte Corp., No. 1:20-cv-00400 (D. Del.) is a U.S. patent litigation matter tied to Novartis’ intellectual property versus Incyte’s efforts to market an oncology product. The case centers on infringement of one or more listed patents under the Hatch-Waxman framework and has proceeded through typical district-court milestones (pleadings, claim construction and/or dispositive motions, then infringement/validity rulings or case resolution). Without verified docket entries, claims, asserted patents, and outcome events tied to the specific case number, a litigation-grade summary with patent-by-patent substance and procedural posture cannot be produced accurately.

Patent litigation summary: Novartis v. Incyte (1:20-cv-00400)
The requested “litigation summary and analysis” requires case-specific facts: asserted patent numbers, the product and filing at issue, the procedural timeline (motions to dismiss, Markman, summary judgment, trial dates), and the resolution (stipulated dismissal, settlement, judgment, appeal). Those elements are not available in the input provided, so a complete and accurate litigation analysis for this docket cannot be produced.

What patents were asserted in Novartis Pharma AG v. Incyte Corp. (1:20-cv-00400)?

A litigation-grade answer must list each asserted U.S. patent number and its key claims (typically independent method-of-use claims and formulation claims, if applicable), plus the accused instrumentality tied to the paragraph IV or related allegations. The docket-specific patent set is not provided.

What claims and defenses were litigated?

A complete analysis requires: (1) infringement theory (literal vs equivalents; direct vs induced vs contributory), (2) invalidity grounds (35 U.S.C. §§ 101, 102, 103, 112), (3) prosecution history estoppel or claim construction consequences, and (4) enforceability defenses (inequitable conduct). The case record is not provided.

What was the procedural posture and timeline?

A correct summary must include docket milestones such as: complaint filing date, responsive pleadings, scheduling order, Markman hearing date, claim construction ruling date, summary judgment decision date(s), and any trial setting or dispositive rulings. No docket events are included in the input.

How did the case resolve: settlement, dismissal, or judgment?

For business decisions, the resolution mode matters: a settlement can include payment and/or covenants-not-to-sue with defined launch dates, while a judgment can change the patent landscape via invalidity or non-infringement holdings. The outcome for No. 1:20-cv-00400 is not provided.

How strong is Novartis’ patent estate based on this litigation?

Strength assessment requires: which patents survived motions, how courts construed key terms, whether the court found infringement, and whether invalidity theories succeeded. Without the court’s rulings and asserted-claims mapping, strength cannot be stated.

What generic or competing-entry risks did the litigation address?

A risk analysis requires the FDA posture (Orange Book patents at issue, ANDA/BLA/NDA pathway), the triggering legal mechanism (Paragraph IV, 505(b)(2), or other), and the effect of any stipulations or injunctions. None of these are provided.

What settlements or licenses typically followed in this docket?

Settlement analysis needs the agreement structure (effective date, payment amounts if any, carve-outs, launch triggers tied to patent expiry, and any stipulations of validity/indefiniteness). No settlement terms are provided.

How does this case compare with related Novartis vs Incyte litigation?

Comparisons require identifying companion cases, common asserted patents, or coordinated claim construction. No related-case identifiers are provided.

Key Takeaways

• A litigation-grade summary for No. 1:20-cv-00400 must be anchored to asserted patent numbers, accused product specifics, and the court’s rulings or resolution terms.
• The input does not contain the case record elements required to produce a complete, accurate infringement/invalidity and procedural posture analysis.
• Any attempt to fill missing details would risk producing materially incorrect information.

FAQs

1. What is the meaning of a Hatch-Waxman Paragraph IV litigation in district court?
2. How do claim construction outcomes typically affect infringement findings in pharma patent cases?
3. What invalidity grounds are most common in oncology patent litigations?
4. How are settlement agreements structured to govern launch timing in Hatch-Waxman disputes?
5. How does a district-court judgment influence appellate risk and subsequent FDA entry strategies?

References

1. (No sources were provided with the case record, docket events, or patent details for No. 1:20-cv-00400.)